Aveva records another year of strong growth in revenues, profits; outlook positive

Aveva Group plc, Cambridge-based worldwide provider of engineering data and design IT systems, said its revenue grew 34% to £127.6m and pre-tax profit was up a striking 83% to £45.0m for the year ended 31 March 2008.

The company said the result reflected growth across all its major geographic regions where it continued to see high levels of demand from all key industries. The mix of licence revenue between initial fees and recurring revenue remained in line with prior years, with recurring revenue of £66.1m (2007 - £52.7m) and initial fees of £52.9m (2007 - £34.2m).

The strength of the performance was reflected in another key metric. Net cash in the bank at the year end doubled to £82.8m.

It is another strong result in a long line of them, but Aveva’s share price was down 23p – almost 2% - in early trading, presumably as some speculators ‘sold into the news’. The share price is still close to 52 week highs. The group is now worth around £840m.

Chairman Nick Prest (pictured) said the Group’s “success for many years has been built upon our world leading technologies developed specifically for the design of complex engineering projects, our excellent customer relationships and the quality of staff we employ.

"Looking ahead the Board believes the outlook for the current year remains very positive for the business. The Oil and Gas, Power and Marine industries remain buoyant, driven by high commodity prices and strong underlying end-user demand.

“The strength of our technology and market position combined with our focus on serving the needs of our target industries today and in the future augur well for the continued success of our business."

He said investment over many years in both its direct sales channel and its product suite have been key to its success.

Investment in R&D increased 21% to £21.3m in the financial year. The year saw major new releases of existing products addressing many customer issues in increasingly large and complex global projects. Aveva also invested in new products aimed at existing vertical markets which address how our customers can manage their high value assets through the full life cycle of ownership from the planning and specification stages through to construction, operations and maintenance.

27 May 2008


Previous articles
Autonomy to beat 1Q09 revenue forecasts; signs licence deal with T-Mobile
More progress in polymer OLED lifetime; red reaches 100,000 hours
Cambridge spin out DanioLabs bought by UK biotech for £15m
CSR completes SiRF merger; global HQ to be in Cambridge; US ops to run out of San Jose
After a tough year MMI raises £1m; reports narrower losses; to change name to reflect new strategy
Fur flies at Meldex as Board fights off dissident shareholder
Silicon Fen shorts: Xaar novel inkjet used to make LCD screen; Alizyme signs deal in Japan; Minster Pharma 1H07 strong cash position
Briefs: Cyclacel closes Cambridge lab; 1Spatial helps redraw municipal boundaries
Intercytex buys stem cell firm Axordia for £1.68m
18 up and comers from around Cambridge make ‘Gauntlet’ shortlist
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • CTM BioTech


Jon Mowles
Commercial Director


CTM BioTech has been established to offer bio-pharmaceutical companies and research organisations a range of services from early stage process development and pre-clinical production through to later stage collaborative projects where CTM can work in partnership with companies to offer services such

[CTM BioTech's profile]


Top20 Index




Currently: 161